Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
Sign Up to like & getrecommendations! Published in 2022 at "NPJ Vaccines"
DOI: 10.1038/s41541-022-00433-9
Abstract: Immune checkpoint inhibitors (ICI) based on anti-CTLA-4 (αCTLA-4) and anti-PD1 (αPD1) are being tested in combination with different therapeutic approaches including other immunotherapies such as neoantigen cancer vaccines (NCV). Here we explored, in two cancer… read more here.
Keywords: cancer; different therapeutic; anti ctla; efficacy ... See more keywords
Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noac107
Abstract: Abstract Background Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Despite maximal treatment, median survival remains dismal at 14–24 months. Immunotherapies, such as checkpoint inhibition, have revolutionized management of some… read more here.
Keywords: cell; neoantigen cancer; testis antigen; tumor ... See more keywords
Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10020196
Abstract: Alternatives to conventional cancer treatments are highly sought after for high-risk malignancies that have a poor response to established treatment modalities. With research advancing rapidly in the past decade, neoantigen-based immunotherapeutic approaches represent an effective… read more here.
Keywords: cancer; optimization; neoantigen based; neoantigen ... See more keywords